Original articleThe clinical course and prognosis of patients with severe, moderate or mild sarcoidosis
References (23)
- et al.
Course and prognosis of sarcoidosis
Am J Med
(1960) - et al.
Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis
Chest
(1990) Pulmonary sarcoidosis: steroid treatment
Clin Dermatol
(1986)- et al.
Prognosis for sarcoidosis in a defined geographical area
Br J Dis Chest
(1987) - et al.
Clinical correlation of serum angiotensinconverting enzyme (ACE) in sarcoidosis. A longitudi nal study of serum ACE, 67Gallium scan, chest roentgenograms and pulmonary function
Chest
(1983) - et al.
Pulmonary function in sarcoidosis: Results with cortisone therapy
Am J Med
(1953) The present status of treatment of pulmonary sarcoidosis: A house divided
Chest
(1977)- et al.
The natural history of pulmonary sarcoidosis
Q J Med
(1960) - et al.
Factors affecting outcome of sarcoidosis
Ann NY Acad Sci
(1986) Course and prognosis of sarcoidosis
Am J Med
(1961)
Course and prognosis of sarcoidosis, Stockholm
Am Rev Respir Dis
Cited by (75)
Neurosarcoidosis and Neurologic Complications of Sarcoidosis Treatment
2024, Clinics in Chest MedicineSarcoidosis among US Hispanics in a Nationwide Registry
2021, Respiratory MedicineSystemic phenotype of sarcoidosis associated with radiological stages. Analysis of 1230 patients
2019, European Journal of Internal MedicineCitation Excerpt :The second consisted of analyze the influence of pulmonary fibrosis (stage IV), that was associated with an older age of diagnosis (55 years vs 47 years in stages II/III, q < 0.001) and a higher use of systemic therapy (81% vs 49%, q = 0.002), with no statistically-significant differences being detected in the systemic phenotype both in the univariate (Supplementary Table 2) and the multivariable (Supplementary Table 3) analysis. Due to the clinical heterogeneity of sarcoidosis, various studies have tried to delineate phenotypic subgroups that could predict the outcome of an individual patient and, therefore, help physicians decide on a specific therapeutic approach and/or the need for referral to highly-specialized healthcare settings [11,15,16]. The first historical attempt at a phenotypical staging of sarcoidosis was proposed by Karl Wurm in 1960 [17], and modified by Guy Scadding in a seminal 1961 publication [14], a classification that relied entirely on the results of the chest radiograph depicting the involvement of the lungs and hilar lymph nodes.
Geoepidemiology of Sarcoidosis
2018, Sarcoidosis: A Clinician's GuideTreatment of Sarcoidosis
2015, Clinics in Chest MedicineAssociation between sarcoidosis and cardiovascular comorbidity: A systematic review and meta-analysis
2020, Heart and LungCitation Excerpt :Additional two papers were found through manual search trial. Finally, we included 14 studies with a total sample size of 18,080,181 ranging from 22 to 18,013,878 for this systematic review and meta-analysis4,17–29 (Table 1, Fig. 1). Seven studies were conducted in Europe, three in Asia, two in South America, and two in the USA.